SAREPTA THERAPEUTICS INC's ticker is SRPT and the CUSIP is 803607100. A total of 375 filers reported holding SAREPTA THERAPEUTICS INC in Q1 2019. The put-call ratio across all filers is 0.75 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $7,961,002 | +24.5% | 65,674 | +17.6% | 0.05% | +39.4% |
Q2 2023 | $6,396,515 | +247.0% | 55,855 | +317.6% | 0.03% | +230.0% |
Q1 2023 | $1,843,338 | +89.1% | 13,374 | +77.8% | 0.01% | +100.0% |
Q4 2022 | $974,701 | -46.2% | 7,522 | -29.3% | 0.01% | 0.0% |
Q4 2020 | $1,813,000 | -96.9% | 10,636 | -97.4% | 0.01% | -97.1% |
Q3 2020 | $58,436,000 | -41.2% | 416,124 | -32.8% | 0.17% | -48.0% |
Q2 2020 | $99,325,000 | -32.7% | 619,467 | -58.9% | 0.33% | +0.9% |
Q1 2020 | $147,480,000 | +32.3% | 1,507,672 | +74.5% | 0.32% | -21.0% |
Q4 2019 | $111,506,000 | +55.3% | 864,123 | -9.4% | 0.41% | +45.4% |
Q3 2019 | $71,805,000 | -55.8% | 953,332 | -10.8% | 0.28% | -54.8% |
Q2 2019 | $162,407,000 | +25.8% | 1,068,816 | -1.3% | 0.62% | +21.4% |
Q1 2019 | $129,089,000 | -29.8% | 1,083,053 | -35.7% | 0.51% | -39.3% |
Q4 2018 | $183,954,000 | -27.8% | 1,685,638 | +6.8% | 0.85% | -11.5% |
Q3 2018 | $254,921,000 | +23.8% | 1,578,360 | +1.3% | 0.96% | +10.6% |
Q2 2018 | $205,947,000 | +69.5% | 1,558,077 | -5.0% | 0.86% | +53.1% |
Q1 2018 | $121,498,000 | +38.1% | 1,639,865 | +3.7% | 0.56% | +42.3% |
Q4 2017 | $87,996,000 | +35.5% | 1,581,525 | +10.5% | 0.40% | +30.6% |
Q3 2017 | $64,947,000 | +1111.7% | 1,431,813 | +800.5% | 0.30% | +1069.2% |
Q2 2017 | $5,360,000 | +46.2% | 159,008 | +28.4% | 0.03% | +44.4% |
Q1 2017 | $3,666,000 | +6.7% | 123,840 | -1.2% | 0.02% | -5.3% |
Q4 2016 | $3,437,000 | -48.5% | 125,302 | +15.3% | 0.02% | -44.1% |
Q3 2016 | $6,676,000 | +400.1% | 108,712 | +55.3% | 0.03% | +385.7% |
Q2 2016 | $1,335,000 | +22.1% | 70,000 | +25.0% | 0.01% | +16.7% |
Q1 2016 | $1,093,000 | -49.4% | 56,000 | 0.0% | 0.01% | -45.5% |
Q4 2015 | $2,160,000 | +4.4% | 56,000 | -13.0% | 0.01% | 0.0% |
Q3 2015 | $2,068,000 | +5.2% | 64,400 | -0.3% | 0.01% | +22.2% |
Q2 2015 | $1,966,000 | – | 64,600 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Ikarian Capital, LLC | 399,400 | $35,962,000 | 5.36% |
Avoro Capital Advisors LLC | 3,125,000 | $281,406,000 | 4.79% |
Varenne Capital Partners | 324,661 | $29,236,000 | 4.34% |
Evolutionary Tree Capital Management, LLC | 96,695 | $8,707,000 | 4.18% |
Ally Bridge Group (NY) LLC | 120,000 | $10,806,000 | 3.78% |
Casdin Capital, LLC | 1,350,000 | $121,568,000 | 3.43% |
Ghost Tree Capital, LLC | 100,000 | $9,005,000 | 3.23% |
GREAT POINT PARTNERS LLC | 145,405 | $13,094,000 | 2.91% |
Camber Capital Management LP | 825,000 | $74,291,000 | 2.55% |
Alpha DNA Investment Management LLC | 17,522 | $1,577,000 | 1.00% |